97 related articles for article (PubMed ID: 20111982)
1. Screening of DNA aptamer which binds to alpha-synuclein.
Tsukakoshi K; Harada R; Sode K; Ikebukuro K
Biotechnol Lett; 2010 May; 32(5):643-8. PubMed ID: 20111982
[TBL] [Abstract][Full Text] [Related]
2. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.
Tsukakoshi K; Abe K; Sode K; Ikebukuro K
Anal Chem; 2012 Jul; 84(13):5542-7. PubMed ID: 22697251
[TBL] [Abstract][Full Text] [Related]
3. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
5. Kinetic capillary electrophoresis-based affinity screening of aptamer clones.
Yunusov D; So M; Shayan S; Okhonin V; Musheev MU; Berezovski MV; Krylov SN
Anal Chim Acta; 2009 Jan; 631(1):102-7. PubMed ID: 19046686
[TBL] [Abstract][Full Text] [Related]
6. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
7. Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method.
Hasegawa H; Sode K; Ikebukuro K
Biotechnol Lett; 2008 May; 30(5):829-34. PubMed ID: 18175068
[TBL] [Abstract][Full Text] [Related]
8. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
9. Abnormal migration of human wild-type alpha-synuclein upon gel electrophoresis.
Moussa CE; Wersinger C; Rusnak M; Tomita Y; Sidhu A
Neurosci Lett; 2004 Nov; 371(2-3):239-43. PubMed ID: 15519765
[TBL] [Abstract][Full Text] [Related]
10. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
Kramer ML; Behrens C; Schulz-Schaeffer WJ
Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
12. Selection and characterization of DNA aptamers against VEGF165 with aptamer blotting method and its application.
Ikebukuro K; Hasegawa H; Sode K
Nucleic Acids Symp Ser (Oxf); 2007; (51):399-400. PubMed ID: 18029755
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
[TBL] [Abstract][Full Text] [Related]
14. Oligomeric alpha-synuclein and its role in neuronal death.
Brown DR
IUBMB Life; 2010 May; 62(5):334-9. PubMed ID: 20209636
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
16. Displacement of protein-bound aptamers with small molecules screened by fluorescence polarization.
Hafner M; Vianini E; Albertoni B; Marchetti L; Grüne I; Gloeckner C; Famulok M
Nat Protoc; 2008; 3(4):579-87. PubMed ID: 18388939
[TBL] [Abstract][Full Text] [Related]
17. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
Schnack C; Danzer KM; Hengerer B; Gillardon F
Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
[TBL] [Abstract][Full Text] [Related]
18. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
19. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
Luk KC; Hyde EG; Trojanowski JQ; Lee VM
Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
[TBL] [Abstract][Full Text] [Related]
20. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
